Clinical Trial Update: Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing neoadjuvant chemotherapy regimens (weekly paclitaxel or eribulin) followed by doxorubicin/cyclophosphamide in locally advanced HER2-nega…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• PACLITAXEL (PACLITAXEL)
• doxorubicin/cyclophosphamide (doxorubicin/cyclophosphamide)

Snippet

Sponsor: NSABP Foundation Inc | Conditions: Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-09-18